BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 18480006)

  • 1. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples.
    Baumhoer D; Tornillo L; Stadlmann S; Roncalli M; Diamantis EK; Terracciano LM
    Am J Clin Pathol; 2008 Jun; 129(6):899-906. PubMed ID: 18480006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more.
    Kandil DH; Cooper K
    Adv Anat Pathol; 2009 Mar; 16(2):125-9. PubMed ID: 19550373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas.
    Wang XY; Degos F; Dubois S; Tessiore S; Allegretta M; Guttmann RD; Jothy S; Belghiti J; Bedossa P; Paradis V
    Hum Pathol; 2006 Nov; 37(11):1435-41. PubMed ID: 16949914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glypican 3: a novel marker in testicular germ cell tumors.
    Zynger DL; Dimov ND; Luan C; Teh BT; Yang XJ
    Am J Surg Pathol; 2006 Dec; 30(12):1570-5. PubMed ID: 17122513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
    Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
    Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma.
    Yan B; Wei JJ; Qian YM; Zhao XL; Zhang WW; Xu AM; Zhang SH
    Ann Diagn Pathol; 2011 Jun; 15(3):162-9. PubMed ID: 21371925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.
    Esheba GE; Pate LL; Longacre TA
    Am J Surg Pathol; 2008 Apr; 32(4):600-7. PubMed ID: 18277882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells].
    Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF
    Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study.
    Zhang L; Liu H; Sun L; Li N; Ding H; Zheng J
    Acta Histochem; 2012 Oct; 114(6):547-52. PubMed ID: 22119409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
    Nassar A; Cohen C; Siddiqui MT
    Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma.
    Shirakawa H; Suzuki H; Shimomura M; Kojima M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
    Cancer Sci; 2009 Aug; 100(8):1403-7. PubMed ID: 19496787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of glypican 3 in hepatoblastoma: an immunohistochemical study of 65 cases.
    Zynger DL; Gupta A; Luan C; Chou PM; Yang GY; Yang XJ
    Hum Pathol; 2008 Feb; 39(2):224-30. PubMed ID: 17949790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy.
    Anatelli F; Chuang ST; Yang XJ; Wang HL
    Am J Clin Pathol; 2008 Aug; 130(2):219-23. PubMed ID: 18628090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrolamellar hepatocellular carcinoma: an immunohistochemical comparison with conventional hepatocellular carcinoma.
    Abdul-Al HM; Wang G; Makhlouf HR; Goodman ZD
    Int J Surg Pathol; 2010 Oct; 18(5):313-8. PubMed ID: 20444731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers.
    Man XB; Tang L; Zhang BH; Li SJ; Qiu XH; Wu MC; Wang HY
    Liver Int; 2005 Oct; 25(5):962-6. PubMed ID: 16162153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.
    Libbrecht L; Severi T; Cassiman D; Vander Borght S; Pirenne J; Nevens F; Verslype C; van Pelt J; Roskams T
    Am J Surg Pathol; 2006 Nov; 30(11):1405-11. PubMed ID: 17063081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.
    Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG
    Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell biological evaluation of liver cell carcinoma, dysplasia and adenoma by tissue micro-array analysis.
    van Dekken H; Verhoef C; Wink J; van Marion R; Vissers KJ; Hop WC; de Man RA; IJzermans JN; van Eijck CH; Zondervan PE
    Acta Histochem; 2005; 107(3):161-71. PubMed ID: 16000213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms.
    Mounajjed T; Zhang L; Wu TT
    Hum Pathol; 2013 Apr; 44(4):542-50. PubMed ID: 23079207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3,940 tissue samples.
    Lugli A; Tornillo L; Mirlacher M; Bundi M; Sauter G; Terracciano LM
    Am J Clin Pathol; 2004 Nov; 122(5):721-7. PubMed ID: 15491968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.